410 related articles for article (PubMed ID: 34817584)
1. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Bauer SR; Walter LC; Ensrud KE; Suskind AM; Newman JC; Ricke WA; Liu TT; McVary KT; Covinsky K
JAMA Netw Open; 2021 Nov; 4(11):e2134427. PubMed ID: 34817584
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
3. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
5. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
[TBL] [Abstract][Full Text] [Related]
6. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
Liu Q; Zhu Y; Liu J; Qi J; Kang J
Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
[TBL] [Abstract][Full Text] [Related]
8. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
Ghadian A; Rezaei M
Inflammopharmacology; 2017 Aug; 25(4):451-458. PubMed ID: 28391389
[TBL] [Abstract][Full Text] [Related]
10. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW
J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210
[TBL] [Abstract][Full Text] [Related]
13. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
14. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
McVary KT; Rogers T; Mahon J; Gupta NK
J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
[TBL] [Abstract][Full Text] [Related]
15. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
16. Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.
Zhang B; Chen X; Liu YH; Gan Y; Liu PH; Chen Z; Xia WP; Dai GY; Ru F; Jiang ZX; He Y
Asian J Androl; 2021; 23(1):80-84. PubMed ID: 32859870
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Associations between Concurrent Changes in Phenotypic Frailty and Lower Urinary Tract Symptoms among Older Men.
Bauer SR; McCulloch CE; Cawthon PM; Ensrud KE; Suskind AM; Newman JC; Harrison SL; Senders A; Covinsky K; Marshall LM
J Frailty Aging; 2023; 12(2):117-125. PubMed ID: 36946708
[TBL] [Abstract][Full Text] [Related]
18. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.
Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116
[TBL] [Abstract][Full Text] [Related]
19. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
20. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
